The CaMK Family Differentially Promotes Necroptosis and Mouse Cardiac Graft Injury and Rejection

Haitao Lu,Jifu Jiang,Jeffery Min,Xuyan Huang,Patrick McLeod,Weihua Liu,Aaron Haig,Lakshman Gunaratnam,Anthony M. Jevnikar,Zhu-Xu Zhang

DOI: https://doi.org/10.3390/ijms25084428

IF: 5.6

2024-04-18

International Journal of Molecular Sciences

Abstract:Organ transplantation is associated with various forms of programmed cell death which can accelerate transplant injury and rejection. Targeting cell death in donor organs may represent a novel strategy for preventing allograft injury. We have previously demonstrated that necroptosis plays a key role in promoting transplant injury. Recently, we have found that mitochondria function is linked to necroptosis. However, it remains unknown how necroptosis signaling pathways regulate mitochondrial function during necroptosis. In this study, we investigated the receptor-interacting protein kinase 3 (RIPK3) mediated mitochondrial dysfunction and necroptosis. We demonstrate that the calmodulin-dependent protein kinase (CaMK) family members CaMK1, 2, and 4 form a complex with RIPK3 in mouse cardiac endothelial cells, to promote trans-phosphorylation during necroptosis. CaMK1 and 4 directly activated the dynamin-related protein-1 (Drp1), while CaMK2 indirectly activated Drp1 via the phosphoglycerate mutase 5 (PGAM5). The inhibition of CaMKs restored mitochondrial function and effectively prevented endothelial cell death. CaMKs inhibition inhibited activation of CaMKs and Drp1, and cell death and heart tissue injury (n = 6/group, p < 0.01) in a murine model of cardiac transplantation. Importantly, the inhibition of CaMKs greatly prolonged heart graft survival (n = 8/group, p < 0.01). In conclusion, CaMK family members orchestrate cell death in two different pathways and may be potential therapeutic targets in preventing cell death and transplant injury.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the impact of cell death (especially programmed necrosis, i.e., necroptosis) on transplantation injury and rejection during organ transplantation. Specifically, the study focused on how members of the calmodulin - dependent protein kinase (CaMK) family promote programmed necrosis and tissue injury and rejection in heart transplantation by forming complexes with receptor - interacting protein kinase 3 (RIPK3). The researchers hope to understand the role of CaMK family members in regulating mitochondrial dysfunction and how these mechanisms affect the cell death process, thereby providing new treatment strategies for preventing transplantation injury.

The main findings of the paper include:
1. **CaMK family members are involved in the programmed necrosis of MVEC (microvascular endothelial cells)**: The study found that TNFα - induced cell death could be inhibited by adding the RIPK1 inhibitor Nec - 1s, confirming that this form of death is indeed programmed necrosis. In addition, the use of the CaMKs inhibitor KN93 significantly reduced cell death, indicating that CaMKs play an important role in programmed necrosis.
2. **RIPK3 and CaMK family members form a complex**: Through co - immunoprecipitation experiments, the researchers found that RIPK3 forms a complex with CaMK1, CaMK2, and CaMK4 under programmed necrosis conditions, indicating that there is an interaction between RIPK3 and CaMKs.
3. **CaMK1 and CaMK4 directly bind to and phosphorylate Drp1, while CaMK2 indirectly regulates the phosphorylation of Drp1 through PGAM5**: The study further revealed the mechanism by which CaMKs promote mitochondrial dysfunction by activating Drp1. CaMK1 and CaMK4 directly activate Drp1, while CaMK2 activates Drp1 indirectly by activating PGAM5.

In conclusion, this study reveals the crucial role of CaMK family members in programmed necrosis, especially their regulation of mitochondrial dysfunction through interaction with RIPK3 and Drp1, thereby promoting cell death. These findings provide a theoretical basis for the development of new treatment strategies for cell death and transplantation injury.